
WilmerHale Reps Apellis Pharmaceuticals in \$60 Million Series E Financing

AUGUST 30, 2017

On August 10, 2017, Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, announced the closing of a \$60 million Series E preferred stock financing.

WilmerHale represented Apellis in this transaction, with a team led by [Stuart Falber](#) and included [Mhairi Immermann](#) and [Alicia Lee](#).

[Read Apellis' press release.](#)